Advertisement

Immuntherapie in der Urologie — Eine kritische Bestandsaufnahme

  • R. Ackermann
  • R. Heicappell
Conference paper

Zusammenfassung

Die Therapie maligner Tumoren durch Aktivierung der Immunabwehr des Wirts ist seit langem Ziel präklinischer und klinischer Studien. Die Effektivität der immuntherapeutischen Ansätze war zu jedem Zeitpunkt bestimmt vom Umfang des Wissens über Anatomie, Physiologie, Pathologie und (Molekular-)biologie des Immunsystems. In einer Übersicht über die Immuntherapie des Nierenzellkarzinoms listete McCune (1983) folgende Therapiemodalitäten auf: BCG-Therapie, Embolisierung und Nephrektomie, Immun-RNA, Immunisierung mit autologen Tumorzellen, Immunisierung mit polymerisiertem Tumorantigen und Therapie mit natürlichem Interferon. Bis auf die Interferontherapie sind alle genannten Verfahren heute bei der Behandlung des metastasierten Nierenzellkarzinoms ohne klinische Bedeutung. Das bedeutet jedoch nicht, daß die Immuntherapie des Jahres 1983 prinzipiell ein Irrweg war, sondern daß die enormen Fortschritte im Wissen über das Immunsystem und seine Regulation in den letzten 10 Jahren zu geänderten oder vollständig neuen Konzepten haben führen müssen (Übersicht bei Ferrini et al. 1990).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlering TE, Dubeau L, Jones PE (1987) A new in vivo model to study invasion and metastasis of human bladder carcinoma. Cancer Res 47: 6660–6665PubMedGoogle Scholar
  2. Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumorin-filtrating lymphocytes in human renal cancer: isolation, characterisation and antitumor activity. Cancer Res 48: 206–214PubMedGoogle Scholar
  3. Bischof-Delaloye A, Delaloye B, Buchegger F et al. (1989) Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 30:1646–1656PubMedGoogle Scholar
  4. Blankenstein T, Rowley DA, Schreiber H (1991) Cytokines and cancer: experimental systems. Curr Opin Immunol 3: 694–698PubMedCrossRefGoogle Scholar
  5. Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 30: 527–530CrossRefGoogle Scholar
  6. Bulbul MA, Huben RP, Murphy GP (1986) Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 334: 231–233CrossRefGoogle Scholar
  7. Bystryn JC (1990) Tumor vaccines. Cancer Met Rev 9: 81–91CrossRefGoogle Scholar
  8. Chodak GW (1989) Intravesical interferon treatment of superficial bladder cancer. Urology 4 (4 Suppl): 84–86CrossRefGoogle Scholar
  9. Clark RL (1980) Cancer 1980. Achievements, challenges and prospects. Cancer 49: 1739–1745CrossRefGoogle Scholar
  10. DeVore DP, Houchens DP, Ovejara AA, Dill GS Jr, Hutson TB (1980) Collagenase inhibitors retarding invasion of a human tumor in nude mice. Exp Cell Biol 48: 367–373PubMedGoogle Scholar
  11. Dilman RO, Beauregard JC, Halpern SE, Clutter M (1986) Toxicities and side effects associated with the intravenous infusions of murine monoclonal antibodies. J Biol Resp Mod 5: 73–84Google Scholar
  12. Feng GS, Gray PW, Shepard HM, Taylor MW (1986) Antiproliferative activity of a hybrid protein between interferon-g and tumor necrosis factor-b. Science 241: 1501–1503CrossRefGoogle Scholar
  13. Ferrini S, Melioli G, Moretta L (1990) Immunotherapy and imunity to cancer: cellular mechanisms. Curr Opin Immunol 2: 683–688CrossRefGoogle Scholar
  14. Fidler IJ (1990a) Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Met Rev 5: 29–49CrossRefGoogle Scholar
  15. Fidler IJ (1990b) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130–6138PubMedGoogle Scholar
  16. Fidler IJ, Heicappell R, Saiki I, Griitter M, Nuesch J (1987) Direct antiproliferative effects of recombinant human interferon-a B/D hybrids on human tumor cell lines. Cancer Res 47: 2020–2027PubMedGoogle Scholar
  17. Frost P, Kerbel RS (1983) Immunology of metastasis. Can the immune response cope with the disseminated tumor? Cancer Metastasis Rev 2: 239–256PubMedCrossRefGoogle Scholar
  18. Glashan GW (1990) A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144/3: 658–661PubMedGoogle Scholar
  19. Gohji K, Nakajima M, Fabra A, Killion J, von Eschenbach A, Fidler IJ (1991) Regulation of metalloproteinase production in metastatic human renal cell carcinoma cells by factors secreted by organ-specific fibroblasts. Proc 82nd Ann Meet Am Assoc Cancer Res (Abstr 401)Google Scholar
  20. Greco WR, Park HS, RustumYM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diaminechtoroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 50: 5318–5327PubMedGoogle Scholar
  21. Grups JW, Schmitz-Dräger BJ, Ebert T, Ackermann R (1986) Biological potential of interferons reievance in the systemic treatment of superficial bladder carcinoma. World J Urol 3: 224–229CrossRefGoogle Scholar
  22. Heicappell R, Ackermann R (1991) Immunomodulation of advanced/progressive renal cell cancer. Curr Opin Urol 1: 38–46CrossRefGoogle Scholar
  23. Heicappell R, Naito S, Creasy AA, Lin LS, Fidler IJ (1987) Antitumor activity of human recombinant tumor necrosis factor on human renal cell carcinoma cell lines derived from a single surgical specimen. J Immunol 138: 1634–1640PubMedGoogle Scholar
  24. Heppner GH, Miller BE (1983) Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 2: 5–23PubMedCrossRefGoogle Scholar
  25. Huland E, Huland H, Heinzer H, Meier T (1991 a) Inhalative Interleukin-2 Gabe zur Lokaltherapie des metastas. Nierenkarzinoms (RCC). Urologe [A] 30 (Suppl A9)Google Scholar
  26. Huland E, Huland H, Meier Th et al. (1991 b) Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol 146: 1631–1636PubMedGoogle Scholar
  27. Jackson AM, Hawkyard SJ, Presott S, Ritchie AWS, James K, Chisholm G (1992) An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J Urol 147: 207–211PubMedGoogle Scholar
  28. Köhler G, Milstein C (1975) Continous culture of fused antibodies secreting antibodies of predefined specificity. Nature 356: 495–497CrossRefGoogle Scholar
  29. Mach JP, Pelegrin A, Buchegger F (1991) Imaging and therapy with monoclonal antibodies in non-hematopoetic tumors. Curr Opin Immunol 3: 685–693PubMedCrossRefGoogle Scholar
  30. Mantovani A (1990) Tumor-associated macrophages. Curr Opin Immunol 2: 689–692CrossRefGoogle Scholar
  31. McCune CS (1983) Immunologic therapies of kidney carcinoma. Semin Oncol 104:431–436Google Scholar
  32. McCune JM, Namikawa R, Kneshima H, Shultz LD, Lieberman M, Weissmann IL (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241: 1632–1639PubMedCrossRefGoogle Scholar
  33. McGee JO’D, Woods JC, Ashall F, Bramwell ME, Harris H (1982) A new marker for human cancer cells. 2. Immunohistochemical detection of the Ca antigen in human tissues with the Cal antibody. Lancet II: 7–10CrossRefGoogle Scholar
  34. McLemore TL, Liu MC, Blacker et al. (1987) Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 47: 5132–5140PubMedGoogle Scholar
  35. Medenica R, Slack N (1985) Clinical results of leukocyte-induced tumor regression in human cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv 21: 53–76CrossRefGoogle Scholar
  36. Morikawa K, Walker SM, Jessup JM, Fidler IJ (1988) In vivo selection of highly metastatic cells from surgical specimens of different human colon carcinomas implanted into nude mice. Cancer Res 48: 1943–1948PubMedGoogle Scholar
  37. Morrison SH, Schlom J (1990) Recombinant chimeric antibodies. Important Adv Oncol 3–18Google Scholar
  38. Mueller BM and Reisfeld RA (1991) Potential of the seid mouse as a host for human tumors. Cancer Metastasis Rev10: 193–200PubMedCrossRefGoogle Scholar
  39. Naito S, von Eschenbach A, Giavazzi R, Fidler IJ (1986) Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109–4115PubMedGoogle Scholar
  40. Oettgen H (1991) Cytokines in clinical cancer therapy. Curr Opin Immunol 3: 699–705PubMedCrossRefGoogle Scholar
  41. Reynolds JC, DelVecchio S, Sahakara H, Lora ME, Carasquillo JA, Neumann RD, Lerson SM (1989) Anti-murine response to mouse monoclonal antibodies: Clinical findings and implications. Int J Rad Appl Instrum [B] 162: 121–125CrossRefGoogle Scholar
  42. Rosenberg SA, Aebersold P, Cornetta (1990) Gene transfer into humans-immunotherapy of patients with advanced malanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transducti Engl J Med 323. 570–5CrossRefGoogle Scholar
  43. Rygaard J, Povlsen CO (1969) Heterotransplantation of human malignant tumor to nude mice. Acta Pathol Microbiol Scand [A] 77: 758–760CrossRefGoogle Scholar
  44. Samelson LE (1989) Lymphocyte activation. Curr Opin Immunol 2: 210–214PubMedCrossRefGoogle Scholar
  45. Scheithauer W, Theyer G, Zechner O, Ludwig B (1988) Experiences with continous administration of recombinant interferon alpha-2C (rIFN-alpha 2) for treatment of patients with advanced transitional cell bladder cancer. J Biol Regul Homeost Agents 22: 67–70Google Scholar
  46. Schlom J,Wunderlich D, TeramotoYA (1980) Generation of human monoclonal antibodies reactive with human mammary carcinoma cell antigens. Proc Natl Acad Sci USA 77: 6841–6845PubMedCrossRefGoogle Scholar
  47. Schmitz-Dräger BJ, Ebert T, Ackermann R (1986) Intravesical treatment of superficial bladder carcinoma with interferons. World J Urol 3: 218–223CrossRefGoogle Scholar
  48. Schreiber H, Gressler VH, Teng MN, Rothstein JL, Rowley DA (1990) Cytokines as effectors in tumor immunity. Immunol Allergy Clin N Am 10: 747–764Google Scholar
  49. Seccamani E,Tattanelli M, Mariani M, Spranzi E, Scasselati GA, Siccardi AG (1989) A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int J Rad Appl Instrum [B] 16: 67–170Google Scholar
  50. Seemann G, Bosslet K, Sedlaczeck H-H (1990) Recombinant monoclonal antibodies in tumor therapy. Behring Inst Mitt 87: 35–47Google Scholar
  51. Shibayama T, Tachibana M, Deguchi N, Jitsukawa S Tazaki H (1991) Scid mice: a suitable model for experimental studies of human malignancies. J Urol 146: 1136–1137PubMedGoogle Scholar
  52. Shimizu H, Wyatt D, Knowles RD, Bucana CD, Stanbridge EJ, Kleinerman ES (1989) Human monocytes selectively bind to cells expressing the tumorigenic phenotype. Cancer Immunol Immunother 28: 185–192PubMedCrossRefGoogle Scholar
  53. Spencer WF,Linehan WM, Walter MM et al. (1992) Immunotherapy with interleukin-2 and a-interferon in patients with metastatic renal cell cancer with in situ primary cancers. J Urol 147: 24–30PubMedGoogle Scholar
  54. Urba WJ, Steis RG, Longo DL et al. (1990) Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res 50: 185–192PubMedCrossRefGoogle Scholar
  55. Van der Bruggen P, Traversari C, Chomez P et al. (1991) A gene encoding for an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647PubMedCrossRefGoogle Scholar
  56. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473–3486PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • R. Ackermann
  • R. Heicappell

There are no affiliations available

Personalised recommendations